pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
TYK2 · news · pharmadog
← back to TYK2
News · TYK2
23
stories
7d
Roivant, the 'inveterate drug hunters', enters commercial era with Lisraya
biospace
14d
6 immunology targets to sustain a mammoth I&I market
biospace
18d
Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare
fiercebiotech
Sep 10, 26
Takeda’s long-term R&D head announces exit after major pipeline reorganization
biospace
Sep 10, 26
Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes
fiercebiotech
Sep 8, 26
Schrödinger births new immunology and inflammation biotech, Tectora Therapeutics
fiercebiotech
Sep 4, 26
This week in charts: China deals, stock flatlines and Lilly’s M&A spree
biopharma dive
Sep 1, 26
Alumis’ TYK2 drug fails in key lupus study
biopharma dive
Sep 1, 26
Alumis' TYK2 drug fails in lupus trial; CEO sees 'clear path forward'
endpoints
Sep 1, 26
Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitor
fiercebiotech
Aug 28, 26
FDA green lights Priovant drug for rare skin disease
biopharma dive
Aug 28, 26
Priovant nabs first FDA approval for targeted tablet in dermatomyositis
biospace
Aug 27, 26
FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults
fda press
Aug 7, 26
Jennifer Taubert announces retirement from J&J; Takeda's global TYK2 leader exits
endpoints
Jul 28, 26
Oak Hill Bio merges with RA Capital SPAC; InnoCare's TYK2 drug hits in Phase 3
endpoints
Jul 27, 26
InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test
fiercebiotech
Jul 17, 26
Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances
biopharma dive
Jul 16, 26
Takeda’s zasocitinib proves ‘top-notch’ for difficult-to-treat psoriasis in phase 3 update
fiercebiotech
Jul 16, 26
Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trial
fiercebiotech
Jun 30, 26
These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.
biopharma dive
Jun 30, 26
Beeline ups its Series A round for immune drug work
biopharma dive
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 11, 26
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
biopharma dive
